Health Technology Assessment (HTA) is intended as a “multi-disciplinary field of policy analysis that studies the medical, social, ethical, and economic implications of development, diffusion, and use of health technology” (INAHTA, 2013). It practically consists in the evaluation of new technologies, in terms of effects and impacts on the healthcare system, with the purpose of informing the policy makers about their cost-effectiveness, safety and value for the patients. Diagnostic and treatment methods, medical equipment, pharmaceuticals, rehabilitation and prevention methods, but also organisational and support systems used to deliver healthcare are examples of “health technologies” subject to assessment.
In 2004, the European Commission and the Council of Ministers recognized HTA as a priority in Europe and, for this reason, encouraged the creation of a network on the topic achieving the following goals: to enhance the efficient use of HTA; to share knowledge about HTA in a sustainable way; to recognize and to promote good practices of HTA.
As a result, a call was launched by the European Commission in 2005 and 35 organisations lead by the Danish Centre for HTA (DACEHTA) in Copenhagen answered. In 2009 the European network for HTA became a stable and sustainable collaboration called EUnetHTA. Member States and several European organisations, including HOPE, took part in the three successive Joint Actions on the topic: the first in 2010, the second in 2012 and the third in 2016.
In parallel, following the adoption of the Cross-border Healthcare Directive (2011/24/EU), a voluntary EU-wide network on HTA composed of national HTA bodies or agencies was established in 2013 to provide strategic and political guidance to the scientific and technical cooperation at EU level.
On 29 March 2017, the European Commission Unit on “Medical products: safety, quality, innovation” (B4) published the preliminary results of the public consultation on Health Technology Assessment (HTA) launched in October 2016 and to which HOPE contributed. On 31 January 2018 the Commission put forward a proposal for a Regulation on Health Technology Assessment (HTA) to which HOPE responded by a Position Paper on HTA.
In its position paper, HOPE welcomed the objectives of the proposal and attaches particular importance to sustainability for high-quality patient care, which also includes safe access to new technologies. HOPE also welcomed the separation made in the proposal of the clinical assessment at EU level and the non-clinical assessment at the national level, insofar as the member states wish to carry out a further examination in their respective health care system. HOPE stressed out different aspects of the proposal that could be improved: more precision is required regarding some key-aspects like the definition of “European stakeholders” and their involvement or regarding the principles of “independence, impartiality and confidentiality” that has to be respected by the Coordination Group. Some precise time limits could also be defined to avoid the legislation to create delays for example in the introduction of primarily new drugs. Due to the complexity of the procedure, HOPE saw the frequent specification of tertiary legislation as problematic an, as far as possible, national legislators should themselves set rules on important issues in the law.
The proposal is discussed by the European Parliament and the Council of Ministers.
Joint Action 1 on Health Technology Assessment
Joint Action 2 on Health Technology Assessment
Joint Action 3 on Health Technology Assessment